Technical Analysis for EXAS - Exact Sciences Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 121.64 | 0.51% | 0.62 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical EXAS trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hammer Candlestick | Bullish | 0.00% | |
Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.51% | |
Stochastic Reached Oversold | Weakness | 0.51% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Possible Pocket Pivot | 2 days ago | |
Reversed from Down | 2 days ago | |
60 Minute Opening Range Breakdown | 2 days ago | |
Down 1 ATR | 2 days ago | |
2x Volume Pace | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/09/2021
Exact Sciences Corporation Description
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Lab Testing Medical Tests Polyp Inflammatory Bowel Disease Pancreatic Cancer Colorectal Cancer Molecular Diagnostics Cancer Screening Genzyme Diagnostic Gastroenterology Mayo Clinic
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 159.54 |
52 Week Low | 35.25 |
Average Volume | 1,743,198 |
200-Day Moving Average | 109.09 |
50-Day Moving Average | 140.11 |
20-Day Moving Average | 140.32 |
10-Day Moving Average | 132.91 |
Average True Range | 8.32 |
ADX | 19.7 |
+DI | 15.84 |
-DI | 41.37 |
Chandelier Exit (Long, 3 ATRs ) | 133.03 |
Chandelier Exit (Short, 3 ATRs ) | 135.09 |
Upper Bollinger Band | 159.41 |
Lower Bollinger Band | 121.24 |
Percent B (%b) | 0.01 |
BandWidth | 27.20 |
MACD Line | -4.27 |
MACD Signal Line | -1.68 |
MACD Histogram | -2.5895 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 140.96 | ||||
Resistance 3 (R3) | 139.27 | 131.13 | 137.74 | ||
Resistance 2 (R2) | 131.13 | 126.21 | 131.98 | 136.67 | |
Resistance 1 (R1) | 126.39 | 123.17 | 128.76 | 128.08 | 135.59 |
Pivot Point | 118.25 | 118.25 | 119.44 | 119.10 | 118.25 |
Support 1 (S1) | 113.51 | 113.33 | 115.88 | 115.20 | 107.69 |
Support 2 (S2) | 105.37 | 110.29 | 106.22 | 106.61 | |
Support 3 (S3) | 100.63 | 105.37 | 105.54 | ||
Support 4 (S4) | 102.32 |